MICHAEL ROBERTSON to Treatment Outcome
This is a "connection" page, showing publications MICHAEL ROBERTSON has written about Treatment Outcome.
Connection Strength
0.041
-
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep; 7(9):e660-e670.
Score: 0.013
-
An Ecological Momentary Assessment Study Investigating Self-efficacy and Outcome Expectancy as Mediators of Affective and Physiological Responses and Exercise Among Endometrial Cancer Survivors. Ann Behav Med. 2020 04 20; 54(5):320-334.
Score: 0.013
-
Impact of Timing of ECMO Initiation on Outcomes After Pediatric Heart Surgery: A Multi-Institutional Analysis. Pediatr Cardiol. 2016 Jun; 37(5):971-8.
Score: 0.010
-
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res. 2004 Aug 15; 10(16):5432-8.
Score: 0.004